These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1034 related articles for article (PubMed ID: 29436178)
1. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178 [TBL] [Abstract][Full Text] [Related]
2. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702 [TBL] [Abstract][Full Text] [Related]
3. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512 [TBL] [Abstract][Full Text] [Related]
4. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687 [TBL] [Abstract][Full Text] [Related]
5. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081 [TBL] [Abstract][Full Text] [Related]
6. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663 [TBL] [Abstract][Full Text] [Related]
7. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Goodman AM; Sokol ES; Frampton GM; Lippman SM; Kurzrock R Cancer Immunol Res; 2019 Oct; 7(10):1570-1573. PubMed ID: 31405947 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers. Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI; Ryan CJ; McKay RR; Master VA; Bilen MA Cancer; 2023 Dec; 129(24):3884-3893. PubMed ID: 37565840 [TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer. Jones NL; Xiu J; Rocconi RP; Herzog TJ; Winer IS Gynecol Oncol; 2020 Feb; 156(2):393-399. PubMed ID: 31882243 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941 [TBL] [Abstract][Full Text] [Related]
11. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer. Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102 [TBL] [Abstract][Full Text] [Related]
12. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. Huang RSP; Haberberger J; Severson E; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Williams E; Elvin J; Vergilio JA; Killian JK; Lin DI; Tse J; Hiemenz M; Owens C; Danziger N; Hegde PS; Venstrom J; Alexander B; Ross JS; Ramkissoon SH Mod Pathol; 2021 Feb; 34(2):252-263. PubMed ID: 32884129 [TBL] [Abstract][Full Text] [Related]
13. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment. Song Y; Gu Y; Hu X; Wang M; He Q; Li Y Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613 [TBL] [Abstract][Full Text] [Related]
14. BAT26 Only Microsatellite Instability with High Tumor Mutation Burden-A Rare Entity Associated with PTEN Protein Loss and High PD-L1 Expression. Kang SY; Kim DG; Kim KM Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142641 [TBL] [Abstract][Full Text] [Related]
15. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies. Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745 [TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of microsatellite instability by next-generation sequencing, MSI PCR and MMR immunohistochemistry in 1942 solid cancers. Kang SY; Kim DG; Ahn S; Ha SY; Jang KT; Kim KM Pathol Res Pract; 2022 May; 233():153874. PubMed ID: 35405622 [TBL] [Abstract][Full Text] [Related]
17. PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score. Cho YA; Lee H; Kim DG; Kim H; Ha SY; Choi YL; Jang KT; Kim KM Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572886 [TBL] [Abstract][Full Text] [Related]
18. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma. Yang X; Lian B; Zhang N; Long J; Li Y; Xue J; Chen X; Wang Y; Wang Y; Xun Z; Piao M; Zhu C; Wang S; Sun H; Song Z; Lu L; Dong X; Wang A; Liu W; Pan J; Hou X; Guan M; Huo L; Shi J; Zhang H; Zhou J; Lu Z; Mao Y; Sang X; Wu L; Yang X; Wang K; Zhao H BMC Med; 2024 Jan; 22(1):42. PubMed ID: 38281914 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. Goodman AM; Piccioni D; Kato S; Boichard A; Wang HY; Frampton G; Lippman SM; Connelly C; Fabrizio D; Miller V; Sicklick JK; Kurzrock R JAMA Oncol; 2018 Sep; 4(9):1237-1244. PubMed ID: 29902298 [TBL] [Abstract][Full Text] [Related]
20. The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients. Zhou F; Huang Y; Cai W; Li J; Su C; Ren S; Wu C; Zhou C Lung Cancer; 2021 Mar; 153():66-72. PubMed ID: 33454519 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]